JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 21 No. 8 763-766
© 1980 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prince, J. R.
Right arrow Articles by Dukstein, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prince, J. R.
Right arrow Articles by Dukstein, W. G.

Pharmacokinetics of Pertechnetate Administered after Pretreatment with 400 mg of Potassium Perchlorate: Concise Communication

John R. Prince, Steven Bancroft and Walter G. Dukstein

King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Research Medical Center, Kansas City, Missouri
Mid-American Nazarene College, Olathe, Kansas

Correspondence: For reprints contact: John R. Prince, PhD, Dept. of Medical Physics, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh, Saudi Arabia.

ABSTRACT

The pharmacokinetic behavior of pertechnetate in normal subjects has been studied. Each received 400 mg of potassium perchlorate 30 min before pertechnetate injection. Timed blood samples were collected and counted. The time-activity curves for whole blood and plasma could both be fitted to an open two-compartment model of the form 3 <- 1 {rightleftarrows} 2, where Compartment 1 refers to the vascular pool, Compartment 2 to the perivascular pool, and Compartment 3 to the urine.

The pharmacokinetic state equation is given by:
Figure 2
Rate constants determined were: k21 = 1.47 hr–1; k12 = 3.11 hr–1; k01 = 0.137 hr–1. The rate constants were the same for the whole-blood and plasma time-activity curves.




This article has been cited by other articles:


Home page
Br. J. Radiol.Home page
H H Boersma, I H Liem, G J Kemerink, P W L Thimister, L Hofstra, L M L Stolk, W L van Heerde, M-T W Pakbiers, D Janssen, A J Beysens, et al.
Comparison between human pharmacokinetics and imaging properties of two conjugation methods for 99mTc-Annexin A5
Br. J. Radiol., August 1, 2003; 76(908): 553 - 560.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1980 by the Society of Nuclear Medicine.